2 Background: Efficacy analyses of the randomized phase III CRYSTAL trial have shown a
significant improvement in progression-free survival (PFS), overall response, and curative …

4000 Background: Efficacy analyses of the randomized phase II OPUS trial have previously
failed to show significant improvements in progression-free survival time (PFS) or overall …

AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy
regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS …

Purpose The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as
first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of …

Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and
leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought …

Background Cetuximab plus chemotherapy is a first-line treatment option in metastatic
KRAS and NRAS wild-type colorectal cancer (CRC) patients. No data are currently available …

3506 Background: The addition of cetuximab to FOLFIRI significantly improved progression-
free survival, overall survival and response in the first-line treatment of patients (pts) with …

Purpose This randomized study assessed whether the best overall response rate (ORR) of
cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior …

Background The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line
Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status …

3506 Background: The CRYSTAL and OPUS studies showed that adding cetuximab to CT in
the first-line treatment of mCRC significantly improved treatment outcome compared with CT …